Literature DB >> 15540891

Malignant melanoma in a black child: predisposing precursors and management.

Olanrewaju T Adedoyin1, Abdul-Wahab B R Johnson, Ayodele I Ojuawo, Enoch A O Afolayan, Kayode A Adeniji.   

Abstract

Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans. To the best of our knowledge, the current report of MM in a two-and-a-half-year-old Nigerian who had a pre-existing congenital giant hairy nevus is probably the first (in an accessible literature) in a black African child. Primary neoplastic transformation and metastatic spread were suggested by the appearance of multiple swellings over the "garment" precursor nevus at the posterior trunk, multiple ipsilateral axillary nodal enlargement, and fresh occipital swellings postadmission. Smaller-sized hyperpigmented lesions with irregular, nonlobulated, and frequently hairy surfaces were also discernible over the upper and lower extremities, but the face, anterior trunk, and mucosal surfaces were relatively spared. A diagnosis of MM was confirmed by the subsequent histopathologic findings from the fine-needle aspirate and biopsy specimens. Chemotherapy was initiated but was truncated shortly after by parent-pressured discharge. Despite the rarity of MM in a tropical African setting where management options are few, the current case underscores the need for a high clinical index of diagnostic suspicion, an early pursuit of investigative confirmation, and prophylactic excision in children with the predisposing skin lesions, like congenital giant hairy nevus. An expounded discourse of the possible precursors and management options of MM is provided. We emphasize the need for institutional cost subsidy for anticancer care in tropical children.

Entities:  

Mesh:

Year:  2004        PMID: 15540891      PMCID: PMC2568537     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  34 in total

1.  Letter: Eruptive nevi.

Authors:  R J Coskey
Journal:  Arch Dermatol       Date:  1975-12

2.  Effect of corticotropin and cortisone on development and progress of pigmented nevi.

Authors:  L GOLDMAN; D F RICHFIELD
Journal:  J Am Med Assoc       Date:  1951-11-03

Review 3.  Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.

Authors:  S A Rosenberg
Journal:  Important Adv Oncol       Date:  1988

4.  Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies.

Authors:  E E Castilla; M da Graça Dutra; I M Orioli-Parreiras
Journal:  Br J Dermatol       Date:  1981-03       Impact factor: 9.302

5.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

Authors:  P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Estrogen replacement therapy withdrawal and regression of metastatic breast cancer.

Authors:  M V Dhodapkar; J N Ingle; D L Ahmann
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

7.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma.

Authors:  A W Boddie; A Cangir
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

Review 9.  Moles and melanoma.

Authors:  S L Chamlin; M L Williams
Journal:  Curr Opin Pediatr       Date:  1998-08       Impact factor: 2.856

10.  Childhood melanoma in Australia.

Authors:  W R McWhirter; C Dobson
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.